On December 23, 2019 Monopar Therapeutics Inc. reported the closing of its initial public offering of 1,277,778 shares of common stock, including the underwriters’ exercise of its over-allotment option, at a public offering price of $8.00 per share before underwriting discounts and commissions (Press release, Monopar Therapeutics, DEC 23, 2019, View Source [SID1234552583]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Total gross proceeds were approximately $10.2 million. Total net proceeds, after deducting underwriting discounts and commissions and estimated offering expenses, are approximately $9.3 million from the initial public offering.

The shares began trading on the Nasdaq Capital Market on December 19, 2019 under the symbol "MNPR."

JonesTrading Institutional Services LLC acted as Lead Bookrunning Manager and Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as Co-Manager for the offering.

The offering of these securities was made only by means of a prospectus. Copies of the final prospectus may be obtained from JonesTrading Institutional Services LLC by calling (212) 907-5332, or by e-mailing [email protected].

A registration statement relating to these securities has been filed with, and declared effective by, the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these shares in any state in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any state.